The medical device sector in the healthcare industry has rapidly advanced in recent years due to its inherent innovation, and Catheter Precision Inc. (NYSE American: VTAK) stands out as a notable player. The company is renowned for its two key products: VIVO™, aiding in ventricular arrhythmia source detection pre-procedure, and LockeT, a closure retention device.
Catheter Precision Inc. (NYSE American: VTAK) recently reported robust initial order momentum for LockeT in Q2 2024 and positive traction for VIVO’s™ initial orders in the latter half of 2024. This development marks a significant milestone, with additional considerations to explore. The distributor validation for LockeT has exceeded projections, instilling notable confidence as the CE Mark launch approaches. See The Complete Report Now.
Management is also forecasting a $10 million run rate by the end of the year, additionally due to the expansion in sales, management anticipates that esteemed academic hospitals will soon be within reach. Moreover, Catheter Precision anticipates favorable feedback on the product’s merits from prestigious global institutions within the next two quarters. The company highlights that sales growth in H2 2024 will hinge significantly on VIVO’s™‘s commercialization progress in new markets.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com